Stockholm, Sweden, 22 October 2021
AnaCardio appoints Patrik Strömberg as CEO.
AnaCardio AB announces today that Patrik Strömberg has been appointed Chief Executive Officer effective as of September 1, 2021. Patrik Strömberg joins AnaCardio from his previous role as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum AB (Sobi). Patrik has extensive experience from the pharmaceutical industry from senior roles in both R&D and Business Development, and he holds a PhD in biochemistry from Karolinska Institutet and an MBA from Stockholm Business School, Stockholm University.
”We are very pleased to announce Patrik´s appointment as CEO of AnaCardio. With his strong background and successful track record from business- and pharmaceutical development, Patrik is the right person to lead AnaCardio´s progress as a clinical stage biopharmaceutical company. AnaCardio now enters a new phase of its journey in developing pioneering treatments to meet the significant unmet needs for heart failure patients around the world,” says Lars Lund Founder and Chairman of AnaCardio AB.
“Building on ground-breaking research, AnaCardio has a promising and innovative platform to improve the lives of heart failure patients that are currently underserved. I am excited for the opportunity to lead AnaCardio and look forward to continue building the team that will bring this concept to patients,” says Patrik Strömberg.
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.
For further information, please contact
Patrik Strömberg, CEO
Telephone: +46 704 156 159